Following angioplasty, drug eluting devices, including stents, balloons, and infusion catheters, have been shown to be effective at inhibiting restenosis resultant from vascular smooth muscle cell proliferation and neointima formation relative to non-drug eluting devices. Drug eluting stents, in particular, have yielded exceptional clinical outcomes in comparison to bare metal stents. Through an improved understanding of the mechanism by which drugs are released and intracellularly delivered, the approach used to develop second generation drug eluting devices can be improved. This workshop will evaluate drug eluting stents formed from biodegradable scaffolds and other methods of controlling the release of drugs after angioplasty. Comparisons will be made in regards to efficacy, safety, and mechanism of action. Speakers will primarily consist of industrial experts who can attest to the effectiveness and practicality of such devices and address regulatory concerns.